

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Clark, *et al.*) Int. Cl: C07D 471/08
Patent No: 7,022,706 B2) U.S. Cl.: 514/252.05
Issued: April 4, 2006) Atty Docket No. T103 1470.2
For: **PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE**

REQUEST FOR CORRECTION OF ERROR IN PATENT

Under 37 CFR § 1.323

Certificate of Correction of Combined Applicant's and Office Mistake

CERTIFICATE OF CORRECTION OFFICE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Assignee of the above-identified patent hereby requests that a Certificate of Correction be issued for this U.S. Patent. We enclose herewith Form PTO SB/44, which provides the changes as they should be listed. These errors are either printing errors made by the USPTO upon printing of the patent or are typographical errors that occurred in good faith. These corrections are of a minor nature and do not constitute new matter or require reexamination.

Assignee requests that the following errors be corrected:

In the Specification:

Column 5, Line 38, replace "substituents A" with -- substituents of A --.

Column 8, Line 26, delete the word "of".

Column 8, Line 33, replace "can using" with – can be synthesized using --.

Column 8, Line 50, delete the word "the".

Column 10, Line 6, replace "*Heteocyclic*" with – *Heterocyclic* --.

Column 10, Line 10, replace "*Heteocyclic*" with – *Heterocyclic* --.

Column 10, Line 19, insert -- of -- between the terms “presence” and “tetrakis”.

Column 12, Line 60, delete the word “of”.

Column 17, Line 36, replace “an” with -- and --.

Column 17, Line 55, replace “Exemplary” with -- Examples --.

Column 18, Line 7, replace the third comma, that which appears following the closed parenthesis, with a period.

In the Claims:

In Claim 1, Column 21, Line 51, the term “represent” should be -- represents -- .

In Claim 1, Column 21, Line 53, “or carbon-carbon double bonds with the proviso that where B' is alkylenic, only one dotted line represents a carbon-carbon double bond, and when B' is ethylenic or acetylenic, no dotted line represents a carbon-carbon double bond” should be deleted.

In Claim 1, Column 21, Line 61, the depicted double bond “-C=C-” should be a triple bond -- -C≡C- --.

In Claim 1, Column 21, Line 63, the open quotation mark “ “ ” should be removed.

In Claim 1, Column 21, Line 65, delete the term “arylalkyl,”.

In Claim 9, Column 23, Line 41, there should be a comma -- , -- after the named compound.

In Claim 10, Column 23, Line 65, there should be a comma -- , -- after the named compound and before the term “and”.

In Claim 20, Column 24, Line 66, the word “represent” should be replaced with -- represents --.

In Claim 20, Column 24, Line 66, there should be a hard return after the comma.

In Claim 20, Column 25, Line 3, the depicted double bond “-C=C-” should be a triple bond -- -C≡C- --.

In Claim 20, Column 25, Line 5, the open quotation mark “ ” should be removed.

In Claim 21, Column 25, Lines 46 through 55, the claim text following “and amino substituents” in line 45 should be deleted.

In Claim 23, Column 26, Line 32, “pharmaceuticl” should be replaced with -- pharmaceutical --.

In Claim 24, Column 26, Line 34, “pharmaceuticl” should be replaced with -- pharmaceutical --.

In Claim 25, Column 26, Line 37, “pharmaceuticl” should be replaced with -- pharmaceutical --.

In Claim 26, Column 26, Line 39, “pharmaceuticl” should be replaced with -- pharmaceutical --.

In Claim 27, Column 26, Line 41, “pharmaceuticl” should be replaced with -- pharmaceutical --.

In Claim 28, Column 26, Line 47, “pharmaceuticl” should be replaced with -- pharmaceutical --.

In Claim 29, Column 27, Line 3, “pharmaceuticl” should be replaced with -- pharmaceutical --.

In Claim 29, Column 27, Line 22, there should be a comma -- , -- after the named compound and before the term “and”.

In Claim 33, Column 28, Line 8, “jis” should be replaced with -- j is --.

In Claim 36, Column 28, Line 14, “jis” should be replaced with -- j is --.

As noted above, these corrections address printing and typographical errors. The Director is authorized to charge the fee for this correction to Deposit Account No. **09-0528** in accordance with the Fee Transmittal submitted herewith.

Respectfully submitted,



Carl B. Massey, Jr.
Reg. No. 44,224
Attorney for Assignee

Date: Jan 4, 2008

Womble Carlyle Sandridge & Rice, PLLC
P.O. Box 7037
Atlanta, Georgia 30357-0037
Telephone: (336) 721-3681 / Facsimile: (336) 726-8074

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO: 7,022,706 B2

DATED: April 4, 2006

INVENTOR(S): Clark, *et al.*

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

Column 5, Line 38, replace "substituents A" with -- substituents of A --.

Column 8, Line 26, delete the word "of".

Column 8, Line 33, replace "can using" with -- can be synthesized using --.

Column 8, Line 50, delete the word "the".

Column 10, Line 6, replace "Heteocyclic" with -- Heterocyclic --.

Column 10, Line 10, replace "Heteocyclic" with -- Heterocyclic --.

Column 10, Line 19, insert -- of -- between the terms "presence" and "tetrakis".

Column 12, Line 60, delete the word "of".

Column 17, Line 36, replace "an" with -- and --.

Column 17, Line 55, replace "Exemplary" with -- Examples --.

Column 18, Line 7, replace the third comma, that which appears following the closed parenthesis, with a period.

In the Claims:

In Claim 1, Column 21, Line 51, the term "represent" should be -- represents -- .

In Claim 1, Column 21, Line 53, "or carbon-carbon double bonds with the proviso that where B' is alkylenic, only one dotted line represents a carbon-carbon double bond, and when B' is ethylenic or acetylenic, no dotted line represents a carbon-carbon double bond" should be deleted.

In Claim 1, Column 21, Line 61, the depicted double bond "-C=C-" should be a triple bond -- -C≡C- --.

In Claim 1, Column 21, Line 63, the open quotation mark " " should be removed.

In Claim 1, Column 21, Line 65, delete the term "arylalkyl".

MAILING ADDRESS OF SENDER:
Carl B. Massey, Jr., Esq. (Reg. No. 44,224)
Womble Carlyle Sandridge & Rice, PLLC
P.O. Box 7037
Atlanta, GA 30357-0037

PATENT NO. 7,022,706 B2
No of additional copies

Page 1 of 2

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO: 7,022,706 B2

DATED: April 4, 2006

INVENTOR(S): Clark, *et al.*

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims:

In Claim 9, Column 23, Line 41, there should be a comma -- , -- after the named compound.

In Claim 10, Column 23, Line 65, there should be a comma -- , -- after the named compound and before the term "and".

In Claim 20, Column 24, Line 66, the word "represent" should be replaced with -- represents --.

In Claim 20, Column 24, Line 66, there should be a hard return after the comma.

In Claim 20, Column 25, Line 3, the depicted double bond "-C=C-" should be a triple bond -- -C≡C- --.

In Claim 20, Column 25, Line 5, the open quotation mark " " should be removed.

In Claim 21, Column 25, Lines 46 through 55, the claim text following "and amino substituents" in line 45 should be deleted.

In Claim 23, Column 26, Line 32, "pharmaceuticl" should be replaced with -- pharmaceutical --.

In Claim 24, Column 26, Line 34, "pharmaceuticl" should be replaced with -- pharmaceutical --.

In Claim 25, Column 26, Line 37, "pharmaceuticl" should be replaced with -- pharmaceutical --.

In Claim 26, Column 26, Line 39, "pharmaceuticl" should be replaced with -- pharmaceutical --.

In Claim 27, Column 26, Line 41, "pharmaceuticl" should be replaced with -- pharmaceutical --.

In Claim 28, Column 26, Line 47, "pharmaceuticl" should be replaced with -- pharmaceutical --.

In Claim 29, Column 27, Line 3, "pharmaceuticl" should be replaced with -- pharmaceutical --.

In Claim 29, Column 27, Line 22, there should be a comma -- , -- after the named compound and before the term "and".

In Claim 33, Column 28, Line 8, "jis" should be replaced with -- j is --.

In Claim 36, Column 28, Line 14, "jis" should be replaced with -- j is --.

MAILING ADDRESS OF SENDER:
Carl B. Massey, Jr., Esq. (Reg. No. 44,224)
Womble Carlyle Sandridge & Rice, PLLC
P.O. Box 7037
Atlanta, GA 30357-0037

PATENT NO. 7,022,706 B2
No of additional copies

Page 2 of 2

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.